Liver transplantation for end-stage hepatic alveolar echinococcosis
10.3969/j.issn.1674-7445.2023254
- VernacularTitle:终末期肝泡型包虫病的肝移植治疗
- Author:
Beichuan PANG
1
;
Na ZHANG
2
;
Bangyou ZUO
1
;
Chong YANG
1
;
Yu ZHANG
1
;
Shaoping DENG
2
Author Information
1. Department of Hepatopancreatobiliary Surgery, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital (School of Medicine, University of Electronic Science and Technology of China), Chengdu 610072, China.
2. .
- Publication Type:Editorial
- Keywords:
Hepatic alveolar echinococcosis;
End-stage;
Orthotopic liver transplantation;
Ex vivo liver resection;
Liver autotransplantation;
Remnant liver volume;
Hepatic vein stent;
Surgical bridging
- From:
Organ Transplantation
2024;15(2):163-170
- CountryChina
- Language:Chinese
-
Abstract:
Hepatic alveolar echinococcosis (HAE) is a common zoonotic endemic parasitic disease in western China. It lacks of typical clinical manifestations in the early stage, and symptoms become prominent during the end stage, with an alarmingly high mortality rate. Among the treatment of end-stage HAE (es-HAE), orthotopic liver transplantation is almost the only radical treatment due to insufficient remnant liver volume, uncontrollable bleeding and difficulty in vascular reconstruction in vivo. However, the shortage of donor liver and long-term postoperative use of immunosuppressants limit its application. The introduction of ex vivo liver resection and autotransplantation (ELRA) resolves this dilemma and significantly broadens the indications of es-HAE. In addition, multiple centers in China have optimized and modified ELRA to further improve the treatment system of es-HAE. At present, liver transplantation (including ELRA) of es-HAE remains a hot topic for clinicians. In this article, orthotopic liver transplantation, ELRA, auxiliary ELRA and other surgical treatment of es-HAE were reviewed, aiming to further enhance the diagnosis and treatment of es-HAE and improve clinical prognosis of the patients.
